Drug intelligence / Profile preview

AK0705

Development stage: Unknown
Lead developer: Ark Biosciences
Modality: Small Molecules
Administration: Inhalation

Overview

**AK0705** is a potential first-in-class neutrophil elastase inhibitor developed by Ark Biosciences for inflammatory respiratory diseases, primarily **chronic obstructive pulmonary disease (COPD)**. It targets key proteases in the inflammatory pathway of immune cells, forming reversible covalent bonds with exceptional picomolar inhibitory activity. Preclinical studies demonstrated efficacy in alleviating lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice by reducing proinflammatory cytokines in bronchoalveolar lavage fluid. Phase I clinical trials are planned for 2024 in China, with ongoing co-development by Calibr (Scripps Research).

Other names: AK 0705AK0705AK-0705

Targets

ELANE (Human Neutrophil Elastase)

Beyond the preview

Go deeper on AK0705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK0705.

Explore the full profile